Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Rachel Soon, Yesterday

Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.

23 Dec 2019
The use of dienogest at 1 mg per day to treat primary dysmenorrhoea is well tolerated and attenuates symptoms of pain, as shown in the results of a phase II trial.

Barriers to opioid use in developing countries identified

Roshini Claire Anthony
24 Feb 2017

There is a lack of use of opioids for pain management in many developing countries mainly due to unfounded prejudices and barriers, according to a presentation at the 7th Association of South-East Asian Pain Societies Congress (ASEAPS 2017) held in Yangon, Myanmar.

“There is a big discrepancy in [opioid use] between developed and developing countries,” said Dr Husni Tanra from the Faculty of Medicine, Hasanuddin University in Makassar, Indonesia. It appears that the more developed the country, the higher the opioid use. Despite the benefits and safety of opioids in pain treatment, opioids are still underused in developing countries, he said.

“There are at least four barriers to using opioids in clinical practice in developing countries,” said Tanra. These are patient, drugs/government, physician, and education barriers.

For a pain management programme to succeed, ie, for patients to acquire good pain management, there are three factors that need to be met – drug availability, education, and institutional policy.

Due to cultural or religious beliefs, some patients believe that pain is inevitable, particularly after surgery, said Tanra. Others feel that if they begin taking opioids too early, the drugs will lose their effect. Some patients may also be of the opinion that opioids are only for patients who are dying, while others fear addiction.

Another barrier is the availability, accessibility, and affordability of opioids in developing countries. Using Indonesia as an example, Tanra stated that the more expensive opioids (eg, slow-release morphine) are more easily available than the more affordable ones (rapid-release morphine).

Inadequate knowledge or prejudices by physicians is yet another barrier to opioid use. One such prejudice, said Tanra, is that when it comes to opioids, many physicians focus on the side effects such as addiction and sedation instead of the potential analgesic effects.

In terms of education, very few institutions focus on pain as a subject, said Tanra. “Pain education for health professionals at all levels has been repeatedly identified as an important step to changing ineffective pain management practices ... Education is the key to eradicate all barriers and prejudices [pertaining to opioid use],” he said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Rachel Soon, Yesterday

Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.

23 Dec 2019
The use of dienogest at 1 mg per day to treat primary dysmenorrhoea is well tolerated and attenuates symptoms of pain, as shown in the results of a phase II trial.